S. Stilgenbauer

Publications900
h-index104
Citations45,782
Highly Influential Citations1,769
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Hallek
  • 1,159 Publications • 54,499 Citations
  • H. Döhner
  • 1,241 Publications • 80,469 Citations
  • J. Byrd
  • 1,447 Publications • 75,146 Citations
  • S. O'brien
  • 1,862 Publications • 87,327 Citations
  • Publications
  • Influence
Genomic aberrations and survival in chronic lymphocytic leukemia.
TLDR
Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival and have implications for the design of risk-adapted treatment strategies.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
TLDR
Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions, and obinutuzumab was superior to rituximab when each was combined with chlorambucil.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
TLDR
The combination of idelalisib and rituximab, as compared with placebo and r ituximabs, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
TLDR
Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
TLDR
In multivariate analysis, unmutated V(H), 17p deletion, 11q deletion, age, WBC, and LDH were identified as independent prognostic factors, indicating a complementary role of V (H) mutation status and genomic aberrations to predict outcome in CLL.
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
TLDR
Functional analysis showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib, which underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrUTinib in CLL.
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
TLDR
Recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.
TP53 mutation and survival in chronic lymphocytic leukemia.
TLDR
CLL with TP53 mutation carries a poor prognosis regardless of the presence of 17p deletion when treated with F-based chemotherapy, and patients with TP 53 mutation should be considered for alternative treatment approaches.
Mutations driving CLL and their evolution in progression and relapse
TLDR
Large sequencing data sets of clinically informative samples enable the discovery of novel genes associated with cancer, the network of relationships between the driver events, and their impact on disease relapse and clinical outcome.
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
TLDR
In multivariate analysis, p53 gene deletion was the strongest prognostic factor for survival and predicts for non-response to therapy with purine analogs and for poor survival in chronic B-cell leukemias.
...
1
2
3
4
5
...